Effect of norepinephrine dosage on mortality in patients with septic shock
Background Use of high-dose norepinephrine is thought to have an immunosuppressive action that increases mortality. This study aimed to evaluate the correlation between norepinephrine dosage and prognosis of patients with septic shock. Methods This study was a nested cohort of the DExmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation (DESIRE) trial. We evaluated 112 patients with septic shock and an initial Sequential Organ Failure Assessment Cardiovascular (SOFA-C) category score > 2 and initial lactate level > 2 mmol/L. We divided the patients into two groups according to the norepinephrine dosage administered over the initial 7 days: high dose (≥ 416 μg/kg/week) (H group, n = 56) and low dose (< 416 μg/kg/week) (L group, n = 56). The primary outcome of interest was 28-day mortality. Secondary outcomes were ventilator-free days, initial 24-h infusion volume, initial 24- to 48-h infusion volume, and the need for renal replacement therapy. For comparisons between the H group and L group, we used the chi-square test or Fisher’s exact test for categorical variables and the t test or Wilcoxon rank sum test for continuous variables. For time-to-event outcomes, Cox proportional hazards models were used. Kaplan-Meier survival curves were created for graphical representation. Results Patient characteristics appeared to be similar between the two groups except for the SOFA-C score and fibrinogen degradation product level. The cumulative incidence of death at 28 days was 29.9% (16 patients) in the L group and 29.7% (15 patients) in the H group (p = 0.99). The median number of 28-day ventilator-free days was 20 (0, 25) in the L group and 16 (0, 22) in the H group (p < 0.05). Initial infusion volume at 0–24 h in the H group was significantly higher than that in the L group (p = 0.004). Infusion volume at 24–48 h in the H group was also significantly higher than that in the L group (p = 0.03). Conclusions No statistically significant difference was observed in 28-day mortality between patients with septic shock treated with high-dose norepinephrine compared with those treated with low-dose norepinephrine. However, the number of ventilator-free days in the L group was higher than that in the H group. Trial registration clinicaltrials.gov Identifier: NCT01760967 Date of trial registration: January 4, 2013..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of Intensive Care - 6(2018), 1 vom: 26. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamamura, Hitoshi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s). 2018 |
|---|
| doi: |
10.1186/s40560-018-0280-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR036662119 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036662119 | ||
| 003 | DE-627 | ||
| 005 | 20230519161557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40560-018-0280-1 |2 doi | |
| 035 | |a (DE-627)SPR036662119 | ||
| 035 | |a (SPR)s40560-018-0280-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamamura, Hitoshi |e verfasserin |0 (orcid)0000-0003-1903-4879 |4 aut | |
| 245 | 1 | 0 | |a Effect of norepinephrine dosage on mortality in patients with septic shock |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2018 | ||
| 520 | |a Background Use of high-dose norepinephrine is thought to have an immunosuppressive action that increases mortality. This study aimed to evaluate the correlation between norepinephrine dosage and prognosis of patients with septic shock. Methods This study was a nested cohort of the DExmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation (DESIRE) trial. We evaluated 112 patients with septic shock and an initial Sequential Organ Failure Assessment Cardiovascular (SOFA-C) category score > 2 and initial lactate level > 2 mmol/L. We divided the patients into two groups according to the norepinephrine dosage administered over the initial 7 days: high dose (≥ 416 μg/kg/week) (H group, n = 56) and low dose (< 416 μg/kg/week) (L group, n = 56). The primary outcome of interest was 28-day mortality. Secondary outcomes were ventilator-free days, initial 24-h infusion volume, initial 24- to 48-h infusion volume, and the need for renal replacement therapy. For comparisons between the H group and L group, we used the chi-square test or Fisher’s exact test for categorical variables and the t test or Wilcoxon rank sum test for continuous variables. For time-to-event outcomes, Cox proportional hazards models were used. Kaplan-Meier survival curves were created for graphical representation. Results Patient characteristics appeared to be similar between the two groups except for the SOFA-C score and fibrinogen degradation product level. The cumulative incidence of death at 28 days was 29.9% (16 patients) in the L group and 29.7% (15 patients) in the H group (p = 0.99). The median number of 28-day ventilator-free days was 20 (0, 25) in the L group and 16 (0, 22) in the H group (p < 0.05). Initial infusion volume at 0–24 h in the H group was significantly higher than that in the L group (p = 0.004). Infusion volume at 24–48 h in the H group was also significantly higher than that in the L group (p = 0.03). Conclusions No statistically significant difference was observed in 28-day mortality between patients with septic shock treated with high-dose norepinephrine compared with those treated with low-dose norepinephrine. However, the number of ventilator-free days in the L group was higher than that in the H group. Trial registration clinicaltrials.gov Identifier: NCT01760967 Date of trial registration: January 4, 2013. | ||
| 650 | 4 | |a Norepinephrine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Septic shock |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ventilator-free days |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kawazoe, Yu |4 aut | |
| 700 | 1 | |a Miyamoto, Kyohei |4 aut | |
| 700 | 1 | |a Yamamoto, Tomonori |4 aut | |
| 700 | 1 | |a Ohta, Yoshinori |4 aut | |
| 700 | 1 | |a Morimoto, Takeshi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Intensive Care |d London : BioMed Central, 2013 |g 6(2018), 1 vom: 26. Feb. |w (DE-627)SPR036658871 |w (DE-600)2739853-5 |x 2052-0492 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2018 |g number:1 |g day:26 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40560-018-0280-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2018 |e 1 |b 26 |c 02 | ||